The leading global voice
We play a major role in bringing the CV community together to drive transformational change.
Together we are stronger
By 2025, our aim is to reduce premature deaths from CVD by at least 25%.
Join the fight
Become a WHF member and help us to build global commitment to address cardiovascular health at the policy level.
We convene and connect our members
To share science, best practice and resources, acting as a global thought leader and catalyst for positive change.
Celebrate World Heart Day
The biggest global awareness-raising campaign for CVD.
Attend the Congress
Join world leaders in heart health, share ideas, network with specialists.
Advocating for heart health
We lead the global advocacy effort for action to prevent, control and reduce the global burden of CVD.
All our programmes and partnerships are aimed at creating awareness of CVD as a priority issue across the globe.
Find out more about our and our members’ work around the world.
Explore everything from toolkits, videos and infographics, to policy reports, factsheets and more.
Advance your professional journey in the world of cardiology and circulatory health at WCC
Date: Thursday, 6 December 2018
Chair: Afzal Hussein Yusufali, UAE
Chair: Mekhman Mamedov, Russia
Talk 1 Primary Prevention – risk scoring
Speaker: Pablo Perel, Switzerland
Talk 2 Post Myocardial Infarction – Who is Safe and Who is Unsafe
Speaker, Country Massoud Ghasemi
Talk 3 Chronic Stable CAD – How Do We Stratify for Risk and Choosing Therapy
Speaker, Country Stefan Achenbach
Talk 4 Should Risk Prediction Paradigms be Different in LMICS
Speaker, Country Tom Gaziano, USA
Chair, Country: Ashley Chin, South Africa
Chair, Country: Jasim Mohamed Al Hashmi, UAE
Talk 1 Is it feasible to reverse the NOAC overdose?
Speaker: Adel Khalifa Hamad, Bahrain
Talk 2 Coronary intervention and AF management: Are the guidelines clear?
Speaker: Nassir Marrouche, USA
Talk 3 Oral anticoagulation in the octogenerians: Is it safe?
Speaker: Ali Oto
Talk 4 Use of anticoagulants in LMIC
Speaker: Ganesan Karthkeyan, India
Date: Friday, 7 December 2018
Chair, Country: Aman Amanullah, Bangladesh
Chair, Country: Mohammad Naeem Aslam, Pakistan
Talk 1 Management of hypertension in pregnancy
Speaker: Natalie Bello, USA
Talk 2 Screening for secondary hypertension
Speaker: Khalida Soomro, Pakistan
Talk 3 Hypertension, Left Ventricular Remodelling and Hypertensive Heart Failure in Black African Patients
Speaker: Dike Ojj, Nigeria
Talk 4 Salt-Sensitive Hypertension in Asia: Prevalence, Genome, and Novel Therapy
Speaker: Tzung-Dau Wang, Taiwan
Chair, Country: Mpiko Ntsekhe, South Africa
Chair, Country: Hesham Ahmed Osman, UAE
Talk 1 Role of Ischemia vs. Stenosis in Driving Therapeutic Decisions
Speaker: Sidney C. Smith Jr, USA
Talk 2 What is Optimal Medical Therapy for CAD and What Should Be the Goals
Speaker: Vinay Bahl, India
Talk 3 Diabetes & CAD: Is there a role for PCI?
Speaker: Haitham Amin
Talk 4 Environment and CAD – Pollution, Climate & Stress
Speaker: Daniel Piñeiro, Argentina
Chair, Country: Andrzej Budaj, Poland
Chair, Country: Ntobeko Ntusi, South Africa
Talk 1 Optimal and Still Practical Ways to Manage Hypertension: What the General Practitioner Needs to do
Speaker: Eugene Yang, USA
Talk 2 Helping Your Patient Becoming Active, Be Compliant with Drugs, and Reduce Stress (general overview in motivational interview, compliance, etc.)
Speaker: Marta Supervia, Spain
Talk 3 Smoking Cessation for Practitioners
Speaker: Ondrej Sochor Czech Republic
Talk 4 How to manage obesity in the office
Speaker: Maria Collazo Puerto Rico
Chair, Country: Sharif Bakir
Chair, Country: Mary Walsh
Talk 1 It is vital, only needs a tweak
Speaker: Jayanthi Jayawardena
Talk 2: It’s waste of time
Speaker: Marildes Castro, Brazil
Date: Saturday, 8 December 2018
Chair, Country: Mohammed Zubaid, Kuwait
Chair, Country: Prakash Deedwania
Talk 1 Renal Denervation – From Hero to Zero – and back? Who, when, how?
Speaker: Deepak Bhatt, USA
Talk 2 One drug, many drugs, low dose, high dose?
Speaker: Clara Chow, Australia
Talk 3 What is the ideal BP?
Speaker: Victor Huckell, Canada
Chair, Country: Koji Hasegawa
Talk 1 The guideline of stroke prevention: all NOACs are same or different?
Speaker: Antoni Martínez-Rubio, Spain
Talk 2 Risk stratification of stroke: more than CHADS and CHA2DS2-Vasc
Speaker: Ali Oto, Turkey
Talk 3 Anti-coagulants in frail, high-aged Asian population
Speaker: Dong (Dede) Zhao, China